In the Spotlight...
Enhanced antitumor immunity of VNP20009-CCL2-CXCL9 via the cGAS/STING axis in osteosarcoma lung metastasis
CTG-initiated cryptic peptide translation up and downstream of a canonical ATG start codon is enhanced by TLR stimulation and induces tumor regression in mice
A bispecific antibody-drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: a phase 1b trial
CD4+ T cells license Kupffer cells to reverse CD8+ T cell dysfunction induced by hepatocellular priming
Previous Digests
Vaccine with ICB sidekick unlock anti-melanoma T cell immunity
July 16, 2025
While personalized neoantigen vaccines have great potential, T cell responses induced by these vaccines often lack strength. Blass, Keskin, et al. aimed to improve T cell antitumor immunity by optimizing vaccine adjuvants and combining the vaccine with ICB. The...
Mutant p53 doesn’t just lose functions - it gains them
July 9, 2025
Mutations in the p53 gene are well known drivers of cancer due to the loss of tumor suppressor functions that are maintained by wild-type p53. However, in recent investigations, Mahat et al. found that a common mutant p53, p53R175H...
CD8s get by without a little help from their friends
July 2, 2025
During acute infections, the primary immune response depends on CD4+ T cells providing help to CD8+ T cells. However, many effector CD8+ T cells (Teff) can respond to pathogens independently of helper responses, but these cells respond poorly to...
Watch ACIR in action
In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.
Watch the 3-minute video explaining ACIR's mission and goal:
In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.
Watch the 6-minute segment on the story behind your favorite digest here:
About ACIR
ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.
Ed Fritsch
Ute Burkhardt
Lauren Hitchings
Gaelle Llambi
Maartje Wouters
Alex Najibi
Katherine J. Turner
Stan Wolf
Paula Hochman
Shishir Pant
Nathan Suek
Morgan Janes
TESTIMONIALS
I'm a big fan of ACIR. I enjoy their weekly newsletters with clear, concise, and insightful summaries, complemented by excellent images. I've even used the images in some of my presentations to explain complex cancer immunotherapy findings. In our rapidly evolving field, their reliable and well-curated updates are invaluable.
Richard W. Vague Professor in Immunotherapy; Professor of PL&M; Director, Center for Cellular Immunotherapies; Director, Parker Institute for Cancer Immunotherapy; University of Pennsylvania Perelman School of Medicine. (Supporter since 2025).
Current Sponsors
